Clinical trials
3 active studies led by Femasys Inc., of 7 in all
Source: ClinicalTrials.gov, Studies with Femasys Inc. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
- 0Reports naming them
- 1Markets in public records
- 0Regions & countries
- 3Active trials they lead[1]
[1] ClinicalTrials.gov, Studies led by Femasys Inc. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
Free public data on Femasys Inc.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
Company facts
- Stock listing
- NASDAQ: FEMY
- Type
- Medical devices
Source: SEC EDGAR, Company filings, CIK 1339005. Retrieved 13 Nov 2026.
See them on ClinicalTrials.gov (opens in a new tab)
US device clearances
4 510(k) clearances and PMA approvals since 2015
- Femvue® Controlled Saline-Air Device (Fsa-300) K253403 · 15 Dec 2025
- Femvue Mini Saline-Air Device K242002 · 22 Nov 2024
- Femchec Controlled Saline-Air Device (Fcd-250) K241693 · 6 Sep 2024
- Femaseed Intratubal Insemination K231730 · 22 Sep 2023
Source: FDA 510(k) and PMA databases, 510(k) clearances, and PMA approvals or changes, since 2015; newest shown. Retrieved 13 Nov 2026.
SEC filings
Annual reports and other filings with the US Securities and Exchange Commission.
Source: SEC EDGAR, Company filings, CIK 1339005.
Trials over time
Studies Femasys Inc. leads, by the year they started and their phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- No phase (devices, observational)
Source: ClinicalTrials.gov, Studies with Femasys Inc. or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets where public records show them
Markets we cover where free public records show Femasys Inc.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
Topics
The topics of the markets Femasys Inc. is in.
From our blog
Stories on the topics Femasys Inc. works in.
Women's Health Supplements: A Growing Focus
Anaemia affects about half a billion women worldwide, and folic acid before pregnancy prevents serious birth…
Read
Breast Cancer Screening and Diagnosis: Closing the Gap
Breast cancer is the most common cancer in women worldwide. Finding it early saves lives, but access to…
Read
Fertility Services: Rising Demand and Access Gaps
About 1 in 6 adults experience infertility. In many countries one IVF cycle costs more than a year's income.
Read